Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years

Manfred P Wirth; William A See; David G McLeod; Peter Iversen; Tom Morris; Kevin Carroll; Casodex Early Prostate Cancer Trialists' Group

Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years

Manfred P Wirth, William A See, David G McLeod, Peter Iversen, Tom Morris, Kevin Carroll, Casodex Early Prostate Cancer Trialists' Group

198 Citationer (Scopus)

Abstract

We evaluated the efficacy and tolerability of 150 mg bicalutamide daily given in addition to standard care, in patients with localized or locally advanced prostate cancer.

Originalsprog	Engelsk
Tidsskrift	Journal of Urology
Vol/bind	172
Udgave nummer	5 Pt 1
Sider (fra-til)	1865-70
Antal sider	6
ISSN	0022-5347
Status	Udgivet - 1 nov. 2004

Fingeraftryk

Dyk ned i forskningsemnerne om 'Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Wirth, M. P., See, W. A., McLeod, D. G., Iversen, P., Morris, T., Carroll, K., & Casodex Early Prostate Cancer Trialists' Group (2004). Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. Journal of Urology, 172(5 Pt 1), 1865-70.

Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. / Wirth, Manfred P; See, William A; McLeod, David G et al.
I: Journal of Urology, Bind 172, Nr. 5 Pt 1, 01.11.2004, s. 1865-70.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning

Wirth, MP, See, WA, McLeod, DG, Iversen, P, Morris, T, Carroll, K & Casodex Early Prostate Cancer Trialists' Group 2004, 'Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years', Journal of Urology, bind 172, nr. 5 Pt 1, s. 1865-70.

@article{532ac24271a04168bcaa0ea82c5b5d1c,

title = "Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years",

abstract = "We evaluated the efficacy and tolerability of 150 mg bicalutamide daily given in addition to standard care, in patients with localized or locally advanced prostate cancer.",

author = "Wirth, {Manfred P} and See, {William A} and McLeod, {David G} and Peter Iversen and Tom Morris and Kevin Carroll and {Casodex Early Prostate Cancer Trialists' Group}",

year = "2004",

month = nov,

day = "1",

language = "English",

volume = "172",

pages = "1865--70",

journal = "Journal of Urology",

issn = "0022-5347",

publisher = "Wolters Kluwer Health",

number = "5 Pt 1",

}

TY - JOUR

T1 - Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years

AU - Wirth, Manfred P

AU - See, William A

AU - McLeod, David G

AU - Iversen, Peter

AU - Morris, Tom

AU - Carroll, Kevin

AU - Casodex Early Prostate Cancer Trialists' Group

PY - 2004/11/1

Y1 - 2004/11/1

N2 - We evaluated the efficacy and tolerability of 150 mg bicalutamide daily given in addition to standard care, in patients with localized or locally advanced prostate cancer.

AB - We evaluated the efficacy and tolerability of 150 mg bicalutamide daily given in addition to standard care, in patients with localized or locally advanced prostate cancer.

M3 - Journal article

C2 - 15540740

SN - 0022-5347

VL - 172

SP - 1865

EP - 1870

JO - Journal of Urology

JF - Journal of Urology

IS - 5 Pt 1

ER -